NEW website coming in September, 2025
Cerebral Innovations
Advancing clinical trial endpoints through cutting-edge, translational sciences.
About Cerebral Innovations
Our Mission
At Cerebral Innovations, our mission is to provide regulatory adhering endpoint solutions with enhanced treatment effect sensitivity.
Our products are primarily designed to meet the requirements for FDA approvals such as New Drug Applications (NDA) or Biologics License Applications (BLA) but can also be used under EMA Marketing Authorisation Applications (MAA).
As such, our products focus on adhering to Patient Focused Drug Development (PFDD), relevant CFR's, GXP, Cybersecurity, and various endpoint development FDA Guidances to ensure we meet Pharmaceutical, Biotech, & CRO requirements.
We welcome academic inquiries to explore how our products can advance research and further enhance patient outcomes.
Experience in 50+ clinical trials across a variety of CNS diseases, including 4 rare/ultrarare disorders.
Our Technology
Our Flagship Software is our digitized Archimedes spiral drawing test (DAST), NeuroQuantix, which is used to quantify tremor, ataxia, dystonia, bradykinesia, and other fine movement disorders. Backed by 100's of scientific publications, our approach provides enhanced sensitivity to ensure drug efficacy is reliably measured and patients receive optimal treatment.
Our Services
We offer a range of services focusing on FDA clinical trials:
- Regulatory adhering implementation of our software
- Implementation of a variety of endpoints
- Contracted Sub-Investigator Services
- Endpoint Training and Maintenance
- Data Management Services
- Consensus/Adjudication Endpoints Services
- Central Rater Committee Assembly
- And, more